Cardiac-Intravascular Forums

0 Replies

Difference between rotaflow and rotaflow II

Equipment: Getinge - Rotaflow II

RE: Getinge - Rotaflow II
Added  Dec 10 2023
0 Replies

Difference between rotaflow and rotaflow II

Equipment: Getinge - Rotaflow II

RE: Getinge - Rotaflow II
Added  Apr 11 2017
0 Replies

ACUDOSE CABINET WILL NOT OPEN DRAWER 3. I TRIED TO RESET BREAKERS, AND REBOOT PC. BUT DRAWER 3 IS NOT FOUND. WE OPENED DRAWERS ALL AROUND IT WITHOUT ISSUE. BUT I CANNOT OPEN DRAWER 3.

Updated  Jun 4 2014
1 Reply

I am looking for a C7 XR OCT system from St. Jude Medical.  I know these are hard to find but wanted to see if anybody knew of any refurbished machines for sale?  Thanks for any help you can give

 

Mark

RE: St. Jude Medical, Inc. - C7-XR OCT
0 Replies

One of the First US cases following FDA clearance performed at University Hospital in Cleveland WESTFORD, Mass., May 20 /PRNewswire/ -- LightLab Imaging, Inc. announced today that Good Morning America featured Dr. Marco Costa, a leading interventional cardiologist and Director of the Interventional Cardiovascular Center at University Hospitals, Case Western Reserve University, using the newest imaging technology available to hospitals in the United States – Optical Coherence Tomography. Dr. Costa is featured performing one of the first procedures in the United States with the new C7-XR™ FD-OCT™ Imaging System and its companion C7 Dragonfly™ Imaging Catheter, following its FDA clearance. The images from this system enabled Dr. Costa to study features of his patient's arterial disease, which provided critical information for his decisions regarding stent size and placement that would not have been possible with other previously available imaging modalities. The procedure was completed successfully and the patient is doing well. For more information on LightLab, please visit www.lightlabimaging.com. The United States Food and Drug Administration cleared the C7-XR FD-OCT Imaging System and companion catheter the week of May 3. The Good Morning America segment featured one of the first cases performed with the system in the U.S. since FDA clearance. About LightLab Imaging, Inc. LightLab Imaging, Inc., based in Westford MA, is the world's leading manufacturer and marketer of Optical Coherence Tomography (OCT) for vascular and other imaging applications. LightLab's OCT systems and imaging catheters are cleared for sale in 40 countries in Europe, Asia, the Middle East and North and South America. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patients' wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more precise information than ever before. For more information, visit www.lightlabimaging.com. About LightLab OCT LightLab Optical Coherence Tomography (OCT) is the Extreme Resolution™ imaging technology for cardiovascular disease diagnosis. LightLab OCT utilizes near-infrared light to create images with 10 times the resolution of Intravascular ultrasound (IVUS). The proprietary LightLab OCT interferometer analyzes reflected light waves to create our extreme resolution Golden Image™ for enhanced diagnosis and treatment decisions. The bandwidths of infrared light utilized for OCT are far higher than ultrasound, resulting in greatly increased image resolution. In fact, LightLab OCT provides intravascular images with 15 micrometers axial resolution, about twice the size of a red blood cell. Despite providing this extreme resolution LightLab OCT is a radiation-free* imaging medium. *OCT is not a source of ionizing radiation, such as X-rays. SOURCE LightLab Imaging, Inc.

RE: St. Jude Medical, Inc. - C7-XR OCT

Ask a Question

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Please review our Privacy Policy for more details.
I Agree